Introduction. Varicose veins of lower extremities (VVLE) are among the most common forms of chronic venous disease (CVD) in pregnant women and are associated with a risk of thrombotic complications that impact maternal and fetal outcomes. Assessing the contribution of risk factors to the development of these complications during pregnancy and the early postpartum period allows for the prevention of these conditions and the reduction of patient risks. Aim of the research. To identify clinically significant risk factors for the development of thrombotic complications of VVLE in pregnant women to optimize preventive and therapeutic measures. Materials and methods. A prospective cohort study of 99 pregnant women with clinical manifestations of CVD class C2 according to the CEAP classification was performed. All patients received therapy with low molecular weight heparins (LMWH) in prophylactic or intermediate doses, depending on body weight. The following clinical risk factors were assessed: age >35 years, body mass index (BMI) ≥30 kg/m2, total score according to the RCOG scale ≥3 (risk scale of venous thromboembolic complications in pregnancy), VVLE onset before pregnancy, aggravated family history of VVLE/VTEC, use of assisted reproductive technologies (ART); adverse outcomes included superficial vein thrombophlebitis (SVT), deep vein thrombosis (DVT), and venous thromboembolic complications (VTEC). Inclusion criteria: confirmed pregnancy at study inclusion; presence of VVLE signs; age over 18 years. Exclusion criteria: extragenital pathology capable of independently influencing the risk of VVLE complications; VVLE complications prior to inclusion in the study. Comparison of indicators is performed using the χ² test. The assessment of the significance of the factor is determined by the odds ratio (OR) with a 95% confidence interval (95% CI). Results. Thrombotic complications were identified in 12 patients, all adverse events being lower limb SVT. BMI ≥30 kg/m2 was associated with a 7-fold increased risk of complications (38% vs 8%; p = 0.008; OR = 7.05; 95% CI 1.81-27.44), and a total RCOG score ≥3 was associated with a 12-fold increased risk (40% vs 3%; p = 0.001; OR = 12.4; 95% CI 2.53-60.66). Age >35 years, VVLE onset before pregnancy, family history of VVLE, and ART use did not significantly affect the incidence of complications. Conclusion. The incidence of VVLE complications in pregnant women in the study cohort was 12.1%, with the vast majority of episodes (91.7%) developing in the third trimester and postpartum period. A BMI ≥30 kg/m² and a total RCOG score ≥3 are significant risk factors for VVLE thrombotic complications, increasing the likelihood of their occurrence by approximately 7-fold and 12-fold, respectively. In contrast, age over 35 years, VVLE onset before pregnancy, a family history of VVLE, and the use of ART did not demonstrate a statistically significant impact on the risk of complications in this study. Combining the RCOG score with BMI analysis allows us to identify high-risk groups of pregnant women with VVLE and justify differentiated thromboprophylaxis and enhanced surveillance, particularly in the third trimester and early postpartum period. Preventive measures carried out in accordance with clinical recommendations (elastic compression, administration of prophylactic or intermediate doses of parenteral anticoagulants) are highly effective in preventing the occurrence of deep vein thrombosis and pulmonary embolism, but have shown questionable effectiveness in preventing the occurrence of thrombophlebitis of subcutaneous veins.